EP0870056B1 - Method for identifying an unknown allele - Google Patents
Method for identifying an unknown allele Download PDFInfo
- Publication number
- EP0870056B1 EP0870056B1 EP96940033A EP96940033A EP0870056B1 EP 0870056 B1 EP0870056 B1 EP 0870056B1 EP 96940033 A EP96940033 A EP 96940033A EP 96940033 A EP96940033 A EP 96940033A EP 0870056 B1 EP0870056 B1 EP 0870056B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alleles
- probes
- allele
- gene
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the invention relates to a method and a kit for identifying an allele of a polyallelic gene.
- HLA human leucocyte antigen
- MHC major histocompatibility complex
- BMT bone marrow transplant
- kidney transplant results have been obtained using sibling donors who are genotypically HLA-identical to the recipient but such donors are available for only about 30% of patients (1-5) .
- BMT using unrelated donors can be successful, but these transplants have higher rates of graft failure, increased incidence and severity of Graft versus Host Disease and more frequent complications related to delayed or inadequate immune reconstitution (4) .
- New molecular biological methods for detection of genetic polymorphism currently provide an opportunity to improve matching of unrelated donors as well as a research tool to investigate the relationship between genetic disparity and transplant complications.
- These molecular typing methods include sequence-specific amplification, hybridisation with oligonucleotide probes, heteroduplex analysis, single strand conformation polymorphism analysis and direct nucleotide sequencing.
- This method utilises both the group-specific and, when present, allele-specific sequence sites in PCR primer design.
- the SSP design is based on the amplification refractory mutation system (ARMS), in which a mismatch at the 3' residue of the primer inhibits non-specific amplification (8,9) .
- ARMS amplification refractory mutation system
- each SSP reaction may not individually provide sufficient specificity to define an allele
- the use of combinations of sequence specific primers allows the amplification of their common sequences to give the desired specificity.
- Another limitation of this method is that it detects a limited number of polymorphic sequences which are utilised to predict the entire sequence. If an unknown allele is present in a particular sample this extrapolation may be incorrect.
- This technique is based on the electrophoretic mobility of single stranded nucleic acids in a non-denaturing polyacrylamide gel, which depends mainly on sequence-related conformation (11-13) .
- the technique can be employed for isolating single alleles which could then be used for further manipulation and analysis such as direct sequencing.
- the pattern of bands obtained after electrophoresis may be diagnostic for an allele (14,15) .
- SSCP DNA single strand to adopt many conformational forms under the same electrophoretic conditions resulting in the presence of several bands from the same product; this makes the identification more difficult.
- sensitivity of this method for detecting mutations or allelic variations there is a physical limitation in the size of the DNA fragment which is of the order of 200-400 base pairs (16).
- the underlying principle of both techniques is the difference in the degree of melting between two alleles (double stranded DNA) which results in a reduction of mobility of the DNA fragments in polyacrylamide gels containing a denaturing reagent (DGGE) or a temperature gradient (TGGE).
- DGGE denaturing reagent
- TGGE temperature gradient
- Mismatched DNA hybrids may be formed at the end of each PCR cycle between coamplified alleles from a particular locus or loci due to primer cross reaction at sites with similar sequences.
- a proportion of sense strands of each allele may anneal to anti-sense strands of different: alleles.
- the banding pattern obtained in PAGE analysis can be useful for identifying the alleles involved in the reaction (22-24) .
- Heteroduplex analysis is an approach that has been utilised to compare HLA genes of a particular donor and recipient.
- HLA genes are amplified, denatured (melted into single strands) and mixed together under conditions that promote renaturation to form double stranded molecules. If the HLA genes of a donor and recipient are similar but not identical, heteroduplexes will form consisting of one strand of an allele of donor origin and a second strand from a different allele of recipient origin (25,26) .
- the sensitivity of this method can be increased by adding DNA from an HLA allele that is not present in the donor or recipient.
- heteroduplex analysis is that it is relatively easy and inexpensive. Limitations of this approach include inability to detect certain HLA disparities, potential detection of irrelevant silent mutations and lack of specific information regarding the nature of the alleles involved.
- SSO typing involves amplification of HLA alleles from a particular locus followed by hybridisation with a panel of oligonucleotide probes to detect polymorphic sequences that distinguish one allele or group of alleles from all others.
- a one step operation may not always differentiate all the known alleles; selected primers can be used to achieve amplification of individual alleles which are then identified by specific probes.
- This second stage of oligotyping is often referred to as high resolution oligotyping (6) .
- DNA templates for sequencing can be produced by a variety of methods, the most popular being the sequencing of cloned genomic or cDNA fragments, or the direct sequencing of DNA fragments produced solely by PCR (as in 1.2 above). These templates represent a single sequence derived from one haplotype. Alleles from both haplotypes of a heterozygous sample may be co-amplified and sequenced together using locus-specific PCR primer.
- allelic HLA class I sequences (32) reveals substitutions throughout the coding region. There is, however, a higher frequency of substitutions within exons 2 and 3 which encode the ⁇ 1 and ⁇ 2 domains of the HLA molecule.
- B and C alleles only 2 pairs out of a total of 6,460 possible combinations can not be distinguished on the basis of nucleotide sequences in exons 2, 3 and 4. However, if the comparison is restricted to exons 2 and 3 this number only increases to 5 pairs of ambiguous sequences. By contrast, when comparison is restricted to either exon 2 or exon 3 alone then the number of ambiguous pairs increases significantly (Table B).
- primers should ensure the effective amplification of target gene fragments. In practice however, trace amplification of competing, cross-hybridising templates may also take place. In addition, due to the shared polymorphic sequence motifs between class I alleles of all three loci, non-specific coamplification of the DNA fragments would hinder specific identification. In practice, it would therefore be advantageous to use a method that allows the separation of the desired product from the undesirable PCR fragments.
- the two polymorphic exons are flanked by introns 1 and 3, and separated by intron 2.
- introns 1 and 3 flanked by introns 1 and 3
- intron 2 and 3 flanked by intron 2.
- the ideal location for primer sites to amplify exons 2 and 3 together as one fragment would be within introns 1 and 3.
- the invention provides a method for identifying an allele of a polyallelic gene, which method comprises:
- the use of a panel of probes which each recognises a different motif allows identification of which motifs are present in the allele.
- the alleles of the polyallelic gene each have a unique combination of motifs and so identification of this combination (or "fingerprint") leads to identification of the unknown allele.
- the invention allows identification of alleles of polyallelic genes, such as the HLA class I genes, which may not contain "allele specific" sequences (i.e. individual sequences which are unique to one particular allele).
- the invention also provides a kit for identifying an allele of an HLA class I gene, which kit comprises a panel of probes, each of which probes recognises a sequence motif that is present in some alleles of the HLA class I gene but not in others, wherein from 20 to 40 of the probes recognise a motif recognised by one of the probes set out in Table 1.
- the kit preferably also comprises a database which indicates which probes in the panel recognise each allele of the HLA class I gene.
- HLA types of the cell lines are HLA types of the cell lines:
- HLA-A, B and Cw alleles are blotted on the same membrane each membrane is hybridised with one probe. Locus specific amplification and allelic separation of the amplified fragments were performed as described in the Example below. DNA was applied to nylon membranes and these were hybridised with URSTO probes, and after washing the chemiluminescence was recorded by autoradiography.
- the invention can be applied to any polyallelic gene system in which there are motifs that are present in some alleles but not in others.
- the invention is mainly applicable to polyallelic systems that have evolved by recombination events and/or by gene conversion in polygenic linked complexes.
- genes to which the invention can be applied are the mammalian MHC genes (e.g. the HLA class I and class II genes), the T cell receptor genes in mammals (36,37) , TAP, LMP, ras, nonclassical HLA class I genes, human complement factor genes C4 and C2, Bf in the HLA complex, and genes located in mitochondrial DNA, bacterial chromosomes and viral DNA.
- Figure 1 illustrates a motif pattern that could have evolved from two alleles, each with four motifs (rectangles), of an ancestral gene.
- the allele specific sequences are targets for SSO and SSP type allele identification techniques, but a minimum of 13 probes would be needed. In the method of the invention, only four probes (indicated on the top of the Figure) would be required to type the entire range. New coherent patterns would indicate new unknown alleles as shown at the foot of the Figure.
- the invention is particularly applicable to HLA class I genes.
- Comparison of HLA-A, B, C allelic sequences reveals a patchwork pattern in which an individual allele comprises a unique combination of sequence motifs, each of which is shared with other alleles, and only a few alleles have a specific sequence that is not present in other alleles (see Arnett and Parham (1995) Tissue Antigens 45 217-257).
- Many authors agree that this characteristic of the HLA class I genes has limited the resolution of all current DNA typing approaches. This feature itself has been exploited to facilitate the identification of all known class I alleles.
- this method differs from any other hitherto described method in that it does not target allele specific regions of the gene (cf SSO and SSP) but utilises recurring motifs which in specific combinations are unique for each allele.
- a very large number of allele specific motif patterns can be generated with probes.
- the number of motif patterns generated by these oligonucleotides are sufficient to identify at least 201 HLA class I alleles.
- the sequences of 40 oligonucleotides are given in Table 1 and the expected patterns shown in Table 2.
- Table 3 shows the location and distribution of the 40 probes in HLA class I genes.
- the probe identity numbers are same as in Table 1; a, b and c indicate the hypervariable sequence regions which are present in the three loci.
- the sequence range refers to the base positions in exons 2 and 3.
- the panel of probes used in the invention generally consists of a sufficient number of probes to uniquely identify the majority of the alleles of the polyallelic gene.
- the panel of probes may be selected so as to uniquely identify at least 50%, at least 75%, at least 90%, at least 95%, at least 99% or 100% of the alleles in the polyallelic system.
- the exact number of probes will vary depending on the gene, but is typically from 10 to 100, preferably from 20 to 70 or from 30 to 50.
- Each probe may recognise a sequence motif that is present in, for example, from 2 to 30, from 2 to 20, for 4 to 20 or from 6 to 16 alleles of the polyallelic gene.
- the panel of probes preferably comprises from 20 to 40 probes which each recognises the motif recognised by one of the probes set out in Table 1.
- Each of the probes in the panel may have a sequence at least 40%, at least 60%, at least 80%, at least 90% or at least 95% identical to either (i) a sequence of one of the probes set out in Table 1 or (ii) a sequence complementary to a sequence of one of the probes set out in Table 1.
- a probe in the panel may have a sequence that is shifted along the HLA class I gene sequence by a certain number of nucleotides compared to a probe set out in Table 1; for example, a probe may be shifted along by from 1 to 10 nucleotides (e.g. from 1 to 5 nucleotides) in either a 5' or a 3' direction compared to a probe set out in Table 1.
- the probes used in the invention may be labelled with any one of a variety of detectable labels in order to facilitate their detection.
- suitable labels include digoxygenin (which may be detected using an antidigoxygenin antibody coupled to alkaline phosphatase), radiolabels, biotin (which may be detected by avidin or streptavidin conjugated to peroxidase) and fluorescent labels (e.g. fluorescein and rhodamine).
- the kit according to the invention may comprise a database which indicates which probes in the panel in the kit recognise each allele of the HLA class I gene.
- the database may be a paper database or a computer database.
- the database may be compiled by examining the sequences of the alleles of the HLA class I gene and noting the probes which would be expected to bind to each allele. The accuracy of a database compiled by such a technique may be verified by experimentally determining which alleles are bound by each probe in the panel.
- Table 2 contains a database showing which of the 40 probes in Table 1 bind specific HLA class I alleles.
- the kit may also contain one or more known alleles as control(s). Such controls can be used to verify that an experiment carried out using the kit has worked correctly.
- the sample of allele contacted with the probes comprises one allele only and is not contaminated by other alleles of the same gene.
- the presence of two similar alleles in the sample can give confusing results and prevent conclusive identification of the alleles.
- Individuals are often heterozygous with respect to the alleles of a particular gene, i.e. individuals often have two different alleles of the same gene, and these alleles need to be separated before contact with the probes.
- MHC major histocompatibility complex
- HLA human leucocyte antigen
- CSA Complementary Strands Analysis
- the different alleles in the original mixture give rise to duplexes having different numbers of mismatches compared to a selected complementary reference DNA strand.
- the separated duplexes can then be analysed by the method of the invention to identify the alleles that were present in the original mixture.
- a preferred form of the CSA method comprises
- Another form of the CSA method comprises
- This form of CSA overcomes the need for solid support systems by conjugating one primer of a pair of primers directly to a high molecular weight molecule (e.g. a protein).
- a high molecular weight molecule e.g. a protein
- the amplified product after hybridisation can be applied directly to a separating gel.
- the high molecular weight conjugates are retained in the gel compared to the duplex without attachment of the high molecular weight molecule.
- a method for separating an allele from a mixture of alleles which method comprises
- the amplification of the single strand can be done, for example, by asymmetric PCR.
- CSA overcomes the need for both solid support systems and conjugation of one primer of a pair to a high molecular weight molecule.
- a primer carrying a ligand such as a hapten in order to facilitate capture of the amplified strand with a receptor such as an antibody and separation of the amplified strand from other components in the amplification mixture.
- the reference allele may be provided in single-stranded form by essentially the same steps as used to provide the test alleles in single-stranded form.
- the CSA method provides an improvement over prior methods for separating alleles.
- the advantages offered by CSA can be summarised as follows:
- the reference allele used in the CSA method generally has a known sequence. Further, the reference allele is usually chosen so as to have a similar allotype to an allotype that at least one of the test alleles is suspected of having. For example, it may be known that a test allele is of the HLA-A02 type from serological data, but it may not be known which of the seventeen A02 sub-types the allele is. In this case, the reference allele may be chosen to be of sub-type A0201 and the method of the present invention could then be used to determine which of the A02 sub-types the test allele is.
- the reference strand may be obtained from (a) a homozygous source, (b) a heterozygous source from which individual strands are isolated by gel separation after amplification steps or (c) DNA synthesis.
- a homozygous source a homozygous source
- a heterozygous source from which individual strands are isolated by gel separation after amplification steps or
- DNA synthesis There are now about 500 internationally recognised cell lines which contain HLA alleles of known sub-type and these cell lines can be used as a source of reference alleles.
- the amplification steps may be carried out by polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the ligand/receptor system used in the CSA method may, for example, be the biotin/streptavidin system.
- Direct conjugation of the primer via a linking group, such as short poly A, to the beads is an alternative.
- one of the primers used in each of the amplification steps may be labelled with biotin, so that when the amplification reaction is carried out double-stranded DNA is produced in which one strand carries a biotin label.
- the double-stranded DNA may then be bound to a solid support coated with streptavidin.
- the solid support used in the CSA method is typically magnetic beads. However, other supports may be used, such as the matrix of an affinity chromatography column.
- the support is in the form of magnetic beads, the two strands of the amplified DNA are separated by attracting the beads to a magnet and washing the beads under conditions such that the double-stranded DNA dissociates into single-strands.
- the dissociation is typically performed by incubating the beads (e.g. three times) under alkaline conditions (e.g. 0.1 M or 0.15 M NaOH) at room temperature for about 5 or 10 minutes.
- alkaline conditions e.g. 0.1 M or 0.15 M NaOH
- the strand that remains attached to the support may be recovered from the support by incubating the support under conditions such that the ligand/receptor complex dissociates.
- the support is typically heated to e.g. 95°C for about 5 minutes; this ensures denaturation of the streptavidin molecule to release the biotinylated single strand which is then recovered.
- the hybridisation step is performed by heating the mixture of strands at about 95°C for about 3 min, at about 70°C for about 5 min and then at about 65°C for about 45 min.
- duplexes are formed which can subsequently be separated by gel electrophoresis (e.g. polyacrylamide gel electrophoresis).
- the electrophoresis may be carried out under denaturing or non-denaturing conditions. The use of denaturing conditions may enhance separation.
- HPLC high pressure liquid chromatography
- the molecule may be a protein such as bovine serum albumin (BSA).
- BSA bovine serum albumin
- the molecular weight of the high molecular weight molecule is such that it causes the DNA molecule to which it is attached to be sufficiently retarded in the separation step (e.g. the electrophoresis step) to allow the DNA molecule to be separated from a duplex without a high molecular weight compound attached.
- the molecular weight of the high molecular weight molecule may be from 10 to 200 kDa, preferably 20 to 100 kDa.
- the invention may be used to match a prospective donor in a tissue or organ transplant operation with a prospective recipient.
- the invention may be used to identify the alleles of the prospective recipient and donor, and hence to determine whether they have compatible alleles.
- the prospective recipient and donor may, for example, be a prospective recipient and donor in a bone marrow or kidney transplant operation.
- the invention may also be used in forensic medicine to determine the origin of a sample of body tissue or fluid, as a follow up technique in treatment of haematological malignancies or inherited disorders, in adoptive immunotherapy, and in identification of bacteria and viruses.
- amplification of exons 2 and 3 is desirable, and the primers were therefore selected to amplify the stretch of the genome between intron 1 and intron 3.
- the localisation and nucleotide sequences of the HLA locus-specific primers used are given in the reagents section.
- PCR reactions were performed in a total volume of 100 ⁇ l using 1 ⁇ g of genomic DNA and 25 pmoles of each locus-specific primer.
- the 3' primer was biotinylated at the 5' end. This arrangement ensures the incorporation of the biotinylated primer onto the amplified antisense DNA strand.
- PCR conditions are given in the following table. Thermocycling conditions A, B and Cw loci 95° C 4 min. 1 cycle 95° C 30 sec. 65° C 50 sec. 33 cycles 72° C 30 sec. 72° C 8 min. 1 cycle
- Magnetic beads with covalently coupled streptavidin on the surface were added to the PCR product and incubated for 30 minutes at 43° C. In this way the amplified PCR product: was immobilised by the interaction of biotin and streptavidin. After incubation, the tubes were placed against a magnet and the beads were washed with washing buffer to remove the remaining PCR reaction components.
- the non-biotinylated DNA strand was then dissociated from the beads by incubation with 0.1 M NaOH at room temperature (r.t.) for 10 minutes. Following this the beads were washed to remove excess NaOH and resuspended in 50 ⁇ l of hybridisation buffer.
- the bead suspension was heated at 95°C for 5 minutes, which ensures denaturation of the streptavidin molecule to release the biotinylated amplified anti-sense single strand which was then removed and placed in a clean tube.
- the isolates contained single biotinylated DNA strands from each allele.
- biotinylated anti-sense strand(s) from above were mixed with a locus specific reference sense strand, Rf A, Rf B and Rf C for HLA-A, B and C respectively (see below), and the mixture was heated at 95°C for 3 min., incubated at 70°C for 5 min. and then at 65°C for 45 min. Under these conditions the sense and anti-sense strands were hybridised.
- the heteroduplexes formed by each allele antisense strand with the locus specific reference sense strand could subsequently be separated from each other by electrophoresis in non-denaturing polyacrylamide gel.
- DNA was extracted from three homozygous 10th IHW cell lines. The following cell lines were selected as locus specific reference DNA: STEINLIN (HLA-A*0101), SP0010 (HLA-B*4402) and STIENLIN (HLA-Cw*0701).
- the PCR conditions for amplification were as above, with the exception that in each case the locus-specific 5' primer was biotinylated (5' end).
- the PCR products were analysed by PAGE to assess the fidelity of the amplification and in all cases a single band was obtained.
- biotinylated single sense strand was isolated as described above and its purity was tested by a heating/annealing cycle of the sample followed by agarose electrophoresis. In each case only a single band of the expected size was observed.
- This step is critical for the separation of the allelic products from heterozygous subjects and from coamplified non-specific products.
- the heteroduplexes formed as described in step 3 were separated from each other by electrophoresis analysis which was performed on an 8% non-denaturing polyacrylamide gel at room temperature (200 volts for 6 hours). The DNA was visualised by ethidium bromide staining and U.V. light.
- heteroduplexes from heterozygote individuals were resolved into two bands, while DNA from homozygote subjects produced a single band.
- the bands were excised from the gel from which the DNA was eluted and blotted on the same membrane for three loci. For heterozygous subjects two dots per locus were prepared. Several subject samples were blotted on each membrane. According to the number of the URSTO probes several membranes were prepared.
- the oligonucleotide probes were labelled with digoxigenin (DIG) at the 3' end (Boehringer, according to specification).
- DIG digoxigenin
- Hybridisation and washing solutions contained TMAC1 (3M), and membranes were hybridised at 54°C and washed at 58°C. Oligonucleotide binding was detected by chemiluminescence; anti-DIG-antibody conjugated to alkaline phosphatase and CSPD were added to membranes. After incubation the chemiluminescence was detected by X-ray films.
- Anti-sense strands from more than 20 samples were isolated, hybridised with the HLA-A locus specific reference sense strand (STEINLIN A*0101), and analysed by 8% non-denaturing polyacrylamide gel electrophoresis. In all cases there was a good correlation between the number of bands observed and' the zygosity of the sample. For example, two bands were seen for heterozygous samples whereas one band was seen for homozygous samples. These bands were always observed in the same area of the gel, the lower half nearest to the anode. A representative autoradiograph from CSA analysis is presented in Figure 2B.
- DNA from 10 homozygous EBV transformed B cell lines set out in the following table was amplified for the HLA-A, B and C loci using locus specific primers and blotted onto 10 nylon membranes.
- DNA was extracted from 63 B-lymphoblastoid cell lines; these included 22 heterozygous and 41 homozygous lines.
- locus specific primers as described above the anti-sense single strands were isolated and hybridised as described above with the appropriate reference strands (A*0101, B*4402, Cw*0701).
- allelic bands were resolved in non-denaturing PAGE and eluted from low melting point agarose as described above.
- the DNA from the isolated bands was blotted on 40 nylon membranes (as in Figure 3) and hybridised with URSTO probes. Alleles were identified by comparison of patterns with those in Table 2.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Testing, Inspecting, Measuring Of Stereoscopic Televisions And Televisions (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
Description
- (i) amplifying the alleles in the mixture of alleles;
- (ii) hybridising single strands of the amplified alleles with a complementary strand of a reference allele to form duplexes; and
- (iii) separating the duplexes.
The location of the target sequences for URSTO probes in HLA class I genes | |||
Sequence range | No. of | Probe identity | |
1. 92-109 | 1 | 31 | |
2. 113-130 | 1 | 2 | |
3. 212-229 | 1 | 36 | |
4. 236-299 | 7 | 24,28,19,35,41,3,33 (a) | |
5. 293-310 | 1 | 29 | |
6. 307-324 | 2 | 4,30 | |
7. 333-430 | 14 | 6,8,10,26,11,20,7,40,9 (b) 23,12,34,43,22 | |
8. 454-471 | 1 | 44 | |
9. 478-495 | 1 | 14 | |
10. 520-578 | 9 | 5,25,32,15,16,13,17,18,42 (c) | |
11. 580-597 | 1 | 37 | |
12. 597-614 | 1 | 45 |
Thermocycling conditions | ||
A, B and Cw loci | ||
95° | 4 min. | 1 cycle |
95° C | 30 sec. | |
65° C | 50 sec. | 33 cycles |
72° C | 30 sec. | |
72° | 8 min. | 1 cycle |
Specificity of the 10 homozygous cell lines used in URSTO | |||
STEINLIN | A*0101 | B8 | C*0701 |
LBUF | A*3001 | B*1302 | C*0601 |
BM14 | A3 | B7 | C7 |
JBUSH | A32 | B38 | C*1203 |
BTB | A2 | B27 | C1 |
WT47 | A32 | B44 | C5 |
SWEIGOO7 | A*2902 | B*4002 | C*02022 |
BM92 | A*2501 | B*5101 | C1 |
SPL | A31 | B62 | C1 |
SPOO10 | A2 | B*4402 | C5 |
Results of 4 URSTO probes | ||||
Allelic specificity | URSTO probes | |||
P3 | P4 | P5 | P29 | |
A*0101 | - | - | - | - |
B8 | - | - | - | - |
C*0701 | - | - | - | - |
A*3001 | - | - | - | + |
B*1302 | - | - | - | - |
C*0601 | - | - | - | - |
A3 | - | - | - | + |
B7 | - | - | - | - |
C7 | - | - | - | - |
A32 | - | + | - | - |
B38 | - | + | - | - |
C*1203 | - | - | - | - |
A2 | - | - | - | + |
B27 | - | - | - | - |
C1 | - | - | - | - |
A32 | - | + | - | - |
B44 | - | - | + | - |
C5 | - | - | - | - |
A*2902 | - | - | - | - |
B*4002 | - | - | - | - |
C*02022 | - | - | - | - |
A*2501 | - | + | - | - |
B5101 | - | + | + | - |
C1 | - | - | - | - |
A31 | + | - | - | + |
B62 | - | - | + | - |
C1 | - | - | - | - |
A2 | - | - | - | + |
B*4402 | - | - | + | - |
C5 | - | - | - | - |
|
10 mM | Tris-HCl pH 7.5 |
1.0 mM | EDTA | |
2.0 M | NaCl | |
Hybridisation buffer | 20 mM | Tris-HCl pH 8.4 |
50 mM | KCl | |
PCR buffer | 20 mM | Tris-HCl pH 8.4 |
50 mM | KCl | |
0.2 mM | | |
TE buffer | ||
10 mM | Tris-HCl pH 7.5 | |
1 mM | EDTA |
Claims (18)
- A method for identifying an allele of a polyallelic gene, which method comprises:(i) contacting the allele with a panel of probes, each of which recognises a sequence motif that is present in some alleles of the polyallelic gene but not in others;(ii) observing which probes recognise the allele so as to obtain a fingerprint of the allele; and(iii) comparing the fingerprint with fingerprints of known alleles;(i) amplifying the alleles in the mixture of alleles;(ii) hybridising single strands of the amplified alleles with a complementary strand of a reference allele to form duplexes; and(iii) separating the duplexes.
- A method according to claim 1 wherein the polyallelic gene is a human leucocyte antigen (HLA) gene.
- A method according to claim 2 wherein the HLA gene is an HLA class I gene or an HLA class II gene.
- A method according to claim 1, 2 or 3 wherein the panel of probes consists of from 20 to 70 probes.
- A method according to claim 3 wherein the HLA gene is an HLA class I gene and the panel of probes comprises from 20 to 40 probes which each recognises the motif recognised by one of the probes set out in Table 1.
- A method according to claim 5 wherein each of the probes has a sequence at least 40% identical to either (i) a sequence of one of the probes set out in Table 1 or (ii) a sequence complementary to a sequence of one of the probes set out in Table 1.
- A method according to claim 5 wherein the panel of probes comprises the 40 probes set out in Table 1.
- A method according to any one of the preceding claims wherein the allele is separated from the mixture of alleles by(i) amplifying the mixture of alleles employing a pair of primers in which one of the primers carries a ligand, so as to produce an amplified mixture of double-stranded alleles in which one of the strands carries a ligand;(ii) contacting the amplified mixture of double stranded alleles with a receptor on a solid support under conditions such that the ligand binds to the receptor;(iii) separating the mixture of double-stranded alleles into single-strands and removing the strands that are not bound to the support by the ligand;(iv) recovering the remaining strands from the support;(v) mixing the recovered strands with a complementary strand of a reference allele so as to form duplexes; and(vi) separating the duplexes.
- A method according to claim 8, modified by recovering the strands that do not bind to the support instead of those that bind to the support, and mixing these recovered strands with the reference allele strand in step (v).
- A method according to any one of the preceding claims wherein the allele to be identified is from a prospective donor or a prospective recipient in a tissue or organ transplant operation.
- A method according to any one of the preceding claims wherein each probe in the panel recognises a sequence motif that is present in from 2 to 20 alleles of the polyallelic gene.
- A kit for identifying an allele of an HLA class I gene, which kit comprises a panel of probes, each of which probes recognises a sequence motif that is present in some alleles of the HLA class I gene but not in others, wherein from 20 to 40 of the probes recognise a motif recognised by one of the probes set out in Table 1.
- A kit according to claim 12 also comprising a database which indicates which probes in the panel recognise each allele of the HLA class I gene.
- A kit according to claim 12 or 13 also comprising a known HLA class I allele as a control.
- A kit according to any one of claims 12 to 14 wherein the panel consists of from 20 to 70 probes.
- A kit according to any one of claims 12 to 15 wherein each of the probes has a sequence at least 40% identical to either (i) a sequence of one of the probes set out in Table 1 or (ii) a sequence complementary to a sequence of one of the probes set out in Table 1.
- A kit according to claim 16 wherein the panel of probes comprises the 40 probes set out in Table 1.
- A kit according to any one of claims 12 to 17 wherein each probe in the panel recognises a sequence motif that is present in from 2 to 20 alleles of the HLA class I gene.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9524381.2A GB9524381D0 (en) | 1995-11-29 | 1995-11-29 | Method for identifying an unknown allele |
GB9524381 | 1995-11-29 | ||
PCT/GB1996/002959 WO1997020197A2 (en) | 1995-11-29 | 1996-11-29 | Method for identifying an unknown allele |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0870056A2 EP0870056A2 (en) | 1998-10-14 |
EP0870056B1 true EP0870056B1 (en) | 2003-05-28 |
Family
ID=10784624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96940033A Expired - Lifetime EP0870056B1 (en) | 1995-11-29 | 1996-11-29 | Method for identifying an unknown allele |
Country Status (7)
Country | Link |
---|---|
US (1) | US6500614B1 (en) |
EP (1) | EP0870056B1 (en) |
AT (1) | ATE241703T1 (en) |
AU (1) | AU7703796A (en) |
DE (1) | DE69628449T2 (en) |
GB (1) | GB9524381D0 (en) |
WO (1) | WO1997020197A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998026091A2 (en) * | 1996-12-12 | 1998-06-18 | Visible Genetics, Inc. | Method and kit for hla class i typing |
EP0953650A1 (en) | 1998-04-20 | 1999-11-03 | Innogenetics N.V. | Method for typing of HLA alleles |
GB9906833D0 (en) * | 1999-03-24 | 1999-05-19 | Clatterbridge Cancer Res Trust | Genetic analysis |
ATE478961T1 (en) * | 1999-04-09 | 2010-09-15 | Innogenetics Nv | METHOD FOR AMPLIFICATION OF HLA CLASS I ALLELES |
US20030143554A1 (en) * | 2001-03-31 | 2003-07-31 | Berres Mark E. | Method of genotyping by determination of allele copy number |
JP2005516300A (en) | 2002-01-25 | 2005-06-02 | アプレラ コーポレイション | How to place, accept, and fulfill orders for products and services |
US20040126794A1 (en) * | 2002-09-26 | 2004-07-01 | Bugawan Teodorica L. | Detection of susceptibility to autoimmune diseases |
KR100571817B1 (en) * | 2003-09-19 | 2006-04-17 | 삼성전자주식회사 | Target nucleic acid detection method using a detection probe that hybridizes to a tag sequence |
EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
US20060235212A1 (en) * | 2004-12-22 | 2006-10-19 | Nickolai Alexandrov | Nucleic acid sequences encoding zinc finger proteins |
WO2007087601A2 (en) * | 2006-01-25 | 2007-08-02 | Ceres, Inc. | Modulating plant protein levels |
US7335760B2 (en) * | 2004-12-22 | 2008-02-26 | Ceres, Inc. | Nucleic acid sequences encoding zinc finger proteins |
US8222482B2 (en) * | 2006-01-26 | 2012-07-17 | Ceres, Inc. | Modulating plant oil levels |
US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
CN101250587B (en) * | 2008-03-26 | 2012-01-04 | 上海市血液中心 | Method for identifying TAP allelomorph by SNPs combination |
CA3211981A1 (en) * | 2013-10-15 | 2015-04-23 | Illumina, Inc. | Major histocompatibility complex single nucleotide polymorphisms |
CN114807335A (en) * | 2013-12-10 | 2022-07-29 | 伊鲁米那股份有限公司 | Kit and probe for identifying alleles of a gene |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310893A (en) * | 1986-03-31 | 1994-05-10 | Hoffmann-La Roche Inc. | Method for HLA DP typing |
GB9024005D0 (en) * | 1990-11-05 | 1990-12-19 | British Bio Technology | Process for amplifying nucleic acid |
DK0514534T3 (en) * | 1990-12-06 | 1999-01-11 | Hoffmann La Roche | Methods and Reagents for HLA DRbeta DNA Typing |
WO1993005179A1 (en) | 1991-08-29 | 1993-03-18 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES:National Institutes of Health | A method for discriminating and identifying alleles in complex loci |
EP0540997A1 (en) * | 1991-11-05 | 1993-05-12 | F. Hoffmann-La Roche Ag | Methods and reagents for HLA class I DNA typing |
IT1252295B (en) * | 1991-11-15 | 1995-06-08 | Schiapparelli Diagnostici Ismu | METHOD FOR DETECTING NUCLEIC ACIDS AND RELATED DIAGNOSTIC KIT |
-
1995
- 1995-11-29 GB GBGB9524381.2A patent/GB9524381D0/en active Pending
-
1996
- 1996-11-29 WO PCT/GB1996/002959 patent/WO1997020197A2/en active IP Right Grant
- 1996-11-29 AU AU77037/96A patent/AU7703796A/en not_active Abandoned
- 1996-11-29 US US09/077,619 patent/US6500614B1/en not_active Expired - Fee Related
- 1996-11-29 AT AT96940033T patent/ATE241703T1/en not_active IP Right Cessation
- 1996-11-29 DE DE69628449T patent/DE69628449T2/en not_active Expired - Fee Related
- 1996-11-29 EP EP96940033A patent/EP0870056B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU7703796A (en) | 1997-06-19 |
GB9524381D0 (en) | 1996-01-31 |
WO1997020197A3 (en) | 1997-06-26 |
ATE241703T1 (en) | 2003-06-15 |
DE69628449T2 (en) | 2004-04-08 |
US6500614B1 (en) | 2002-12-31 |
EP0870056A2 (en) | 1998-10-14 |
WO1997020197A2 (en) | 1997-06-05 |
DE69628449D1 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0870056B1 (en) | Method for identifying an unknown allele | |
US5629149A (en) | DNA sequence-based HLA typing method | |
JP3093265B2 (en) | Methods for comparing genotypes by comparing nucleotide sequences of members of a gene family and kits therefor | |
AU724531B2 (en) | Multiplex amplification of short tandem repeat loci | |
US8394582B2 (en) | Identification of fetal DNA and fetal cell markers in maternal plasma or serum | |
US6200747B1 (en) | Method and kits for detection of fragile X specific, GC-rich DNA sequences | |
US5578443A (en) | DNA sequence-based HLA typing method | |
WO2003027309A2 (en) | Diagnostic probe detection system | |
AU2002327046A1 (en) | Diagnostic probe detection system | |
Middleton et al. | Modification of an HLA‐B PCR‐SSOP typing system leading to improved allele determination | |
CA2139433A1 (en) | Methods of single nucleotide primer extension to detect specific alleles and kits therefor | |
US9637788B2 (en) | Discrimination of blood type variants | |
JPH10506541A (en) | Probe system capable of performing HLA-DR type determination and type determination method using the probe | |
US6503707B1 (en) | Method for genetic typing | |
US6994958B2 (en) | Methods for separating and/or identifying DNA molecules | |
EP0672179B1 (en) | Nucleic acid analysis | |
Middleton | HLA typing from serology to sequencing era | |
Williams et al. | Development of PCR‐SSOP for the identification of HLA‐A* 02 subtypes and determination of HLA‐A* 02 frequencies within different ethnic populations | |
JP4889258B2 (en) | Method for determining resistance to the onset of bovine leukemia | |
Clay et al. | PCR‐SSO typing for DR4‐Dw subtypes: application to unrelated bone marrow transplant donor selection | |
Browning et al. | Low resolution HLA-A locus typing by multiplex ARMS PCR | |
JP2002101889A (en) | New genotype-determining method | |
Bugawan et al. | PCR-based DNA typing for the HLA-A locus using immobilized oligonucleotide probes (reverse dot blot) | |
Middleton et al. | Determination of HLA-B alleles by digoxigenin-labelled oligonucleotide probes and comparison with serological result | |
Eliaou et al. | HLA-A2 subtyping by non-radioactive reverse dot-blot procedure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980602 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20010522 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20030528 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030528 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69628449 Country of ref document: DE Date of ref document: 20030703 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030828 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030828 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030828 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030828 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030908 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20031201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040302 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20081127 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20081112 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20081126 Year of fee payment: 13 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20091129 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100730 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091129 |